Which one is better, axitinib/axitinib or sunitinib?

Axitinib/Axitinib and sunitinib are both targeted drugs used to treat advanced renal cell carcinoma (RCC). There are certain differences in their respective mechanisms of action, efficacy and side effects, so selection needs to be made based on specific circumstances in clinical application.

Axitinib is a drug that selectively inhibits multiple tyrosine kinases. It mainly targets the vascular endothelial growth factor receptor (VEGFR) and also has certain inhibitory effects on other related tyrosine kinases. Its effectiveness has been verified in multiple clinical trials, especially in patients who have received previous treatment, showing good efficacy. In clinical studies, axitinib has shown clear advantages in prolonging progression-free survival (PFS) and overall survival (OS).

In contrast, sunitinib is also a targeted drug that mainly works by inhibitingVEGFR and several other key tyrosine kinases. Sunitinib is widely used in treatment-naive patients, and its efficacy has been supported by a large number of studies. Clinical data shows that sunitinib can effectively control the disease and slow down tumor progression in the first-line treatment.

In terms of efficacy, some studies have shown that axitinib may be more advantageous than sunitinib in certain patient groups. For example, axitinib may provide better treatment results in patients who have already received other treatments. However, this does not mean that axitinib is better than sunitinib in all cases, as individual patient differences, tumor biology, and previous treatment history will all affect the final treatment effect.

Side effects are a factor that must be considered when choosing anticancer drugs. Common side effects of axitinib include high blood pressure, fatigue, diarrhea, oral ulcers, etc., while sunitinib may cause rash, loss of appetite, fatigue, etc. The nature of the side effects of the two drugs differs, and clinicians need to tailor treatment based on the patient's specific health and tolerance.

In addition, the patient's quality of life is also an important factor to consider when selecting anticancer drugs. Differences in the impact of the two drugs on quality of life are also worthy of attention. Studies have shown that axitinib may have a relatively small impact on quality of life in some aspects, but this still needs to be evaluated based on individual patient feedback.

When choosing axitinib or sunitinib, clinicians usually consider multiple factors such as the patient's condition, previous treatment history, physical condition, tolerance to the drug, and personal preference. In addition, regular monitoring of treatment effects and side effects is essential to adjust treatment regimens.

Reference materials:https://pmc.ncbi.nlm.nih.gov/articles/PMC8419787/